Back to Agenda
The Changing Landscape for Bioinnovation: The Emergence of Small Pharma, Strategic Alliances, and Precision Medicine (Part 1 of 2)
Session Chair(s)
Kenneth Getz, MBA
Tufts Center for the Study of Drug Development, Tufts University School of Medicine, United States
The landscape for pharmaceutical R&D is shifting dramatically: From large pharmaceutical companies to small and specialty pharmaceutical companies, from vertically integrated companies to collaborative partnerships and innovation networks, and from high volume markets to targeted and precision medicines. This two-part forum will explore the impact of these changes on the R&D landscape.
This first forum will focus on the small and specialty pharmaceutical company sector as the new engine of bioinnovation, and will look at the role of innovative collaborative partnerships and strategic alliances in the discovery, development, and commercialization of new medical products.
Part 2 will take place on Tuesday at 10:30 AM (Session #252).
Learning Objective : Identify shifts in pharmaceutical R&D; Discuss the impact of these changes on the R&D landscape; Examine the role of small and specialty pharma in the discovery, development, and commercialization of new medical products.
Speaker(s)
Kenneth I. Kaitin, PHD
Professor and Senior Fellow, Tufts Center for the Study of Drug Development, United States
Panelist
Ellen G Feigal, MD, MSC
Principal, NDA Partners LLC, United States
Panelist
David G Shoemaker, PHD
Senior Vice President, R&D, Rho, Inc., United States
Panelist
Bruce M. Wagman, MBA, RN, RAC
, Labcorp Drug Development, United States
Panelist
Have an account?